SpyGlass Pharma Earnings Call Transcripts
Fiscal Year 2026
-
A novel intraocular lens with integrated drug delivery targets a $13 billion market by simplifying glaucoma and cataract treatment in a single procedure, showing strong clinical efficacy and safety. Phase III trials are underway, with a potential launch in 2029.
-
A novel drug-eluting intraocular lens for cataract and glaucoma is in phase III trials, with strong early data showing long-term efficacy and streamlined surgical workflow. Market access is supported by new reimbursement codes, and a robust cash position funds development through launch. Four-year clinical data and a next-gen drug ring system trial are key near-term catalysts.
-
A novel intraocular lens system delivers long-term glaucoma therapy during cataract surgery, showing strong efficacy and safety in early trials. The product integrates into standard workflows, expands surgeon access, and has clear regulatory and reimbursement paths, with pivotal phase III data and commercialization milestones expected through 2029.
-
The company is advancing a combined cataract and glaucoma treatment with a three-year drug-eluting intraocular lens, showing superior IOP reduction and high patient retention without additional therapy. A second-generation removable drug ring system is in early trials, and strong financials support operations through 2028.
-
Significant progress includes timely phase III trial enrollment, strong long-term efficacy data, and a clear regulatory and reimbursement strategy. Upcoming milestones feature new clinical trials and key data readouts, with positive surgeon feedback and streamlined policy positioning.